PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29141539-3	2018	MATERIALS AND METHODS: Monophosphate analogs of fludarabine, gemcitabine, and dexamethasone were combined with a carbodiimide reagent in the presence of imidazole to produce reactive intermediates that were subsequently covalently bound to monoclonal anti-IGF-1R or anti-EGFR IgG-immunoglobulin.	Carbodiimides	113-125	epidermal growth factor receptor	Homo sapiens	271-275	
30264501-4	2018	Further, anti-EGFR antibody (Cetuximab, C225) was covalently linked to the Cys-AuNP by carbodiimide-mediated amidation protocol to yield the C225-AuNP immunoprobe.	Carbodiimides	87-99	epidermal growth factor receptor	Homo sapiens	14-18	
32436550-4	2020	When compared to conventional carbodiimide chemistry, this conjugation approach leads to the generation of nanoparticles with a higher surface loading of cetuximab F(ab) and with markedly improved ability to bind to the target epidermal growth factor receptor.	Carbodiimides	30-42	epidermal growth factor receptor	Homo sapiens	227-259	
27574398-3	2016	MATERIALS AND METHODS: The covalent immunopharmaceutical, dexamethasone-(C21-phosphoramide)-[anti-EGFR] was synthesized by reacting dexamethasone-21-monophosphate with a carbodiimide reagent to form a dexamethasone phosphate carbodiimide ester that was subsequently reacted with imidazole to create an amine-reactive dexamethasone-(C21-phosphorylimidazolide) intermediate.	Carbodiimides	170-182	epidermal growth factor receptor	Homo sapiens	98-102